The QualityStocks Daily Monday, April 25th, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(NKTX) $18.7200 +140.93%

QualityStocks(WSFT) $0.1890 +80.00%

TradersPro(XAIR) $7.8300 +12.02%

The QualityStocks Daily Stock List

RiceBran Technologies (RIBT)

Stocks That Move, StreetInsider, QualityStocks, MarketBeat, Wall Street Resources, TraderPower, Tiny Gems, Alliance Advisors, Street Insider, Investing Futures, Greenbackers, DreamTeamNetwork and BUYINS.NET reported earlier on RiceBran Technologies (RIBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RiceBran Technologies (NASDAQ: RIBT) (FRA: NTQ3) is a specialty ingredient firm that together with its subsidiaries, is engaged in the research, processing, development and marketing of rice bran-based nutrients.

The company, which is based in The Woodlands, Texas was incorporated in 1998 on March 18th. Prior to its name change in October 2012, the company was called NutraCea. A strategic change in focus to a company that’s only focused on rice bran bio-refining from a multidivisional firm was the reason behind the name change.

The firm markets proprietary whole food dietary supplements obtained from nutrient-dense stabilized rice bran and provides its products under the animal nutrition category and the food ingredients category. It operates in the consumer packaged goods industry and its products are used by feed and pet food manufacturers, nutraceutical makers and food manufacturers.

RiceBran Technologies’ products include a complete rice bran nutritional package obtained from further processing of stabilized rice bran, known as RiBalance; a highly nutritious, lipid and carbohydrate rich RiBalance fraction dubbed RiFiber and a fiber and protein rich insoluble derivative of ProRyza and RiBalance products, which comprises of derivatives of protein/fiber blends and protein. Apart from this, the company also extracts defatted rice bran and crude rice bran oil from rice bran, which is processed into compounded animal nutrition products for poultry, sheep, swine, cows and horses.

The company manufactures products that are not only organic but also gluten-free, GMO-free, sustainability-oriented and suitable for vegans, which makes them very popular as they can be consumed by all.

RiceBran Technologies (RIBT), closed Monday's trading session at $0.6287, up 18.2879%, on 2,175,828 volume. The average volume for the last 3 months is 2.132M and the stock's 52-week low/high is $0.27/$1.83.

Cango (CANG)

The Online Investor, StreetInsider, StocksEarning, InvestorPlace, Zacks, RedChip, QualityStocks, MarketBeat, FreeRealTime and BUYINS.NET reported earlier on Cango (CANG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cango Inc. (NYSE: CANG) (FRA: 9C0A) is a service firm that operates as an automotive transaction service platform that links car buyers, financial institutions and original equipment manufacturers and dealers in China.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in August 2010 by Xiao Jun Zhang and Jia Yuan Lin. It operates as a part of the technology sector, under the technology services sub-industry and serves consumers in China.

Its services are mainly made up of automotive transaction facilitation, after-market services facilitation and automotive financing facilitation. It also provides integrated solutions which support the cycle of automotive financing transactions. These include delinquent asset management services, credit servicing, credit assessment and credit origination. The company also offers additional services, which include the facilitation of care purchases for individuals who’d like to buy cars, vehicle sourcing, warehousing and logistics support for dealers. This is in addition to facilitating after-market services to individuals who’d like to buy a vehicle, which include facilitating the sale of insurance policies from firms or insurance brokers. The products provided via its platform include automotive and personal accident insurance.

The enterprise’s extensive, technology-enabled service offerings in the automotive value chain allow the company to attract more participants to its platform and improve the engagement of existing participants. Its comprehensive data insight built upon its technology also offers the company a competitive edge in possible value-added service offerings, which may be useful in encouraging more investments into the firm.

Cango (CANG), closed Monday's trading session at $3.32, up 40.678%, on 5,472,938 volume. The average volume for the last 3 months is 5.396M and the stock's 52-week low/high is $1.95/$7.22.

Cabaletta Bio Inc. (CABA)

MarketBeat, StreetInsider, QualityStocks and FreeRealTime reported earlier on Cabaletta Bio Inc. (CABA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cabaletta Bio Inc. (NASDAQ: CABA) is a biopharmaceutical firm that is focused on discovering and developing T cell therapies for B cell-mediated autoimmune illnesses.

The firm has its headquarters in Philadelphia, Pennsylvania and was incorporated in April 2017 by Aimee Payne, Steven Nichtberger and Michael C. Milone. Prior to its name change in August 2018, the firm was known as Tycho Therapeutics Inc. The firm serves consumers in the United States.

The company explores the potential of engineered T cell therapies to offer a durable and curative treatment for these autoimmune ailments. Its technology uses cells that have been designed to bind to and eliminate disease-causing auto-antibodies.The company is party to a research agreement with The Regents of the University of California; and a collaboration agreement with the University of Pennsylvania.

The enterprise’s product pipeline comprises of a product dubbed DSG3/1-CAART, which has been developed to treat mucocutaneous pemphigus vulgaris; and a formulation known as FVIII-CAART, which has been developed to treat Hemophilia A. It also develops a preclinical stage product dubbed MuSK-CAART, to treat myasthenia gravis. In addition to this, the enterprise develops DSG3-CAART, which is undergoing a phase 1 trial evaluating its effectiveness in treating mucosal pemphigus vulgaris.

Recently, the firm announced its 2021 third quarter financial results, with its CEO noting that they were focused on providing a highly effective and possibly curative therapy without generalized suppression, for the treatment of mucosal pemphigus vulgaris. The success and approval of its DSG3-CAART formulation will bring in more investments into the firm while also providing effective treatment to patients suffering from this indication.

Cabaletta Bio Inc. (CABA), closed Monday's trading session at $1.59, up 18.6567%, on 801,849 volume. The average volume for the last 3 months is 789,648 and the stock's 52-week low/high is $1.2762/$14.9499.

Dogness International (DOGZ)

TradersPro, MarketClub Analysis, StreetInsider, QualityStocks, TopPennyStockMovers, StockMarketWatch, Schaeffer's and InvestorPlace reported earlier on Dogness International (DOGZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dogness International Corp. (NASDAQ: DOGZ) is focused on designing, manufacturing and selling smart and fashionable products for pets.

The firm has its headquarters in Dongguan, the People’s Republic of China and was incorporated in 2003 by Shilong Chen. The firm serves consumers around the globe.

The company’s objective is to build the future of pet commerce by innovating its traditional product line while leveraging its proven research and development capabilities to gain leadership in pet Internet of Things. It produces high-quality harnesses, collars and leashes that are comfortable, beautiful and designed to ensure pet owners’ peace of mind and pet safety. The company operates through its subsidiaries.

The enterprise produces products in Special function, Holiday, LED, Luxury, Elegance, Cat and Classic series. They include pet harnesses, pet collars, retractable leashes, lanyards and pet leashes; pet belt ribbons, elastic belts, laces, high-grade textiles and computer jacquard ribbons; gift suspenders; pet charms and mouth covers; climbing hooks; pet shampoos; and intelligent pet products like pet water fountains, app-controlled pet feeders and smart pet toys. It also provides the anti-shock leash, the H2 smart harness and the C2 smart collar. The enterprise has designed its smart collars to allow owners to find their dogs easily. It provides its products to retailers and wholesalers.

The company recently announced that it would be expanding the availability of its smart pet products online and in stores, building on its existing supplier relationships. This move will help extend the company’s consumer reach, which will not only bring in more revenue into the company but also drive its growth.

Dogness International (DOGZ), closed Monday's trading session at $4.04, up 15.0997%, on 11,397,027 volume. The average volume for the last 3 months is 11.353M and the stock's 52-week low/high is $1.30/$8.98.

Aterian Inc. (ATER)

QualityStocks, Tip.us, Stocks to Buy Now, SmallCapRelations, SeriousTraders, NetworkNewsWire, InvestorBrandNetwork, MarketClub Analysis, StocksEarning, Schaeffer's, Trades Of The Day, Daily Trade Alert, Kiplinger Today, InvestorPlace and MissionIR reported earlier on Aterian Inc. (ATER), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aterian Inc. (NASDAQ: ATER) (BMV: ATER) is a technology-enabled consumer products firm that operates a consumer product platform.

The firm has its headquarters in New York, the United States and was incorporated in 2014 by Yaniv Sarig Zion. Prior to its name change in April 2021, the firm was known as Mohawk Group Holdings Inc. The firm serves consumers around the globe, with a primary focus on North America.

The company is focused on building, acquiring and partnering with e-commerce brands. Its AIMEE cloud-based platform (artificial intelligence marketplace e-commerce engine) uses natural language processing, machine learning and data analytics to design, develop, market and sell different products on various online marketplaces, including Walmart, Shopify and Amazon. The company generates the majority of its revenues from online sales of different consumer products.

The enterprise’s platform provides health and beauty products; home and kitchen appliances; kitchenware, heating and cooling products; and air quality appliances like air conditioners, humidifiers and dehumidifiers. It offers its products under the Healing Solutions, Spiralizer, Pohl and Schmitt, Pursteam, Mueller, Australia, RIF6, Xtava, Vremi, hOmeLabs, Holonix and Truweo brands.Truweo is an e-commerce brand in the personal wellness and health category. The enterprise is also involved in the sale of essential oils.

The firm is planning to enter into a partnership agreement with Recurrent Ventures Inc., for strategic marketing efforts. This move will drive more sales for Aterian’s products through Recurrent Venture’s portfolio of online editorial publications and create good opportunities for the growth of both companies, which may bring in more investments into both firms.

Aterian Inc. (ATER), closed Monday's trading session at $5.11, up 16.4009%, on 22,395,380 volume. The average volume for the last 3 months is 21.517M and the stock's 52-week low/high is $2.10/$26.1821.

Finch Therapeutics (FNCH)

MarketBeat reported earlier on Finch Therapeutics (FNCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Finch Therapeutics Group Inc. (NASDAQ: FNCH) is a clinical-stage microbiome therapeutics firm that is focused on the development of new orally administered biological medications for the treatment of various indications.

The firm has its headquarters in Somerville, Massachusetts and was incorporated in 2014 by Zain Kassam, Tom Borody, Andrew Noh and Mark Smith. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is party to collaboration and license agreements with the University of Minnesota; Skysong Innovations LLC; and Takeda Pharmaceutical Company Ltd. It is focused on delivering microbial therapies to patients with unmet medical needs.

The enterprise’s product pipeline is comprised of orally administered formulations, FIN-525 and TAK-524, which target consortia product candidates for the treatment of Crohn’s disease and ulcerative colitis. It also develops an enriched consortia formulation which is orally administered and is dubbed FIN-211, to help treat autism spectrum disorder. In addition to this, the enterprise is involved in the development of an orally administered microbiome capsule known as CP101, which is undergoing phase III clinical trials for the treatment of chronic Hepatitis B virus. This formulation is also being developed for the treatment of Clostridioides difficile infection.

The firm is currently focused on executing its strategic objectives, which include advancing its Autism spectrum disorder and Clostridioides difficile infection programs. The success of these programs will help deliver on the firm’s mission to serve patients. This is in addition to boosting the firm’s revenues and benefiting its shareholders.

Finch Therapeutics (FNCH), closed Monday's trading session at $2.57, off by 6.8841%, on 72,012 volume. The average volume for the last 3 months is 70,950 and the stock's 52-week low/high is $2.52/$22.10.

Neoleukin Therapeutics (NLTX)

TradersPro, QualityStocks, MarketBeat, StockMarketWatch, PennyTrader Publisher, BUYINS.NET, CoolPennyStocks, Daily Markets, HotOTC, MadPennyStocks, MarketClub Analysis, Momentum Traders, BullRally, PennyStockVille, Wise Alerts, StockEgg, StockRich, StreetInsider, The Penny Play, UltimatePennyStock and PennyInvest reported earlier on Neoleukin Therapeutics (NLTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Neoleukin Therapeutics Inc. (NASDAQ: NLTX) is a biopharmaceutical firm that is focused on the development of immunotherapies for autoimmunity disorders, inflammation and cancer, through the use of protein design technology.

The firm has its headquarters in Seattle, Washington and was incorporated in December 2003 by Umut Ulge, Carl Walkey and Daniel-Adriano Silva. Prior to its name change in August 2019, the firm was known as Aquinox Pharmaceuticals Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company is developing medications for the treatment of immunological disorders to help meet significant medical needs. It uses a range of computational techniques to develop therapeutic proteins which demonstrate pharmaceutical properties that can offer potentially superior therapeutic benefit over other proteins.

The enterprise’s lead product candidate is a de novo protein dubbed NL-201, which has been designed to mimic cytokines interleukin therapeutic activity for interleukin-2 (IL-2) and interleukin-15 (IL-15). This formulation holds promise in combination with cell therapy to maintain and expand populations of NK cells (natural killer cells) and transplanted CAR-T cells. It has been developed for the treatment of different types of cancer, including melanoma and renal cell carcinoma.

The company recently presented preclinical data for its NL-201 formulation, demonstrating that this candidate has the potential to treat hematologic cancers. The approval of this formulation will encourage more investments into the company and bolster its growth significantly.

Neoleukin Therapeutics (NLTX), closed Monday's trading session at $1.34, off by 2.1898%, on 341,223 volume. The average volume for the last 3 months is 198,034 and the stock's 52-week low/high is $1.30/$13.40.

Vincerx Pharma (VINC)

MarketBeat reported earlier on Vincerx Pharma (VINC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vincerx Pharma Inc. (NASDAQ: VINC) is a clinical-stage biopharmaceutical firm that is focused on researching and developing therapies for the treatment of cancer.

The firm has its headquarters in Palo Alto, California and was incorporated in 2018, on December 19th by John C. Byrd, Soo In Hwang, Tom C. Thomas, Raquel E. Izumi and Ahmed M. Hamdy. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company is focused on addressing the unmet medical needs for treating cancer. It uses its extensive oncology and development expertise to advance new therapies. The company’s pipeline is derived from a license agreement with Bayer.

The enterprise’s product pipeline comprises of a small molecule drug conjugate dubbed VIP236, for the treatment of solid tumors; an oral PTEFb/CDK9 inhibitor known as VIP217; and a cyclin-dependent kinase-9 inhibitor dubbed VIP152, for the treatment of patients with advanced cancer. VIP152 inhibits RNA polymerase II (RNAPII) phosphorylation, which helps prevent transcription elongation and blocks the expression of genes which promote cancer. It also develops VIP924 and VIP943 for the treatment of hematologic malignancies.

The firm recently released preliminary clinical data for its VIP152 candidate and is currently focused on aligning its clinical trial design with the Project Optimus Initiative by the FDA. The success and approval of this formulation will not only benefit patients with different types of cancer but also bring in more investors into the firm.

Vincerx Pharma (VINC), closed Monday's trading session at $2.65, up 3.1128%, on 70,544 volume. The average volume for the last 3 months is 70,544 and the stock's 52-week low/high is $2.50/$18.4265.

Genasys Inc. (GNSS)

MarketBeat, InvestorPlace and FreeRealTime reported earlier on Genasys Inc. (GNSS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Genasys Inc. (NASDAQ: GNSS) (FRA: G66) is a firm that is engaged in the provision of essential communications software and hardware solutions.

The firm has its headquarters in San Diego, California. Prior to its name change in 2010, the firm was known as LRAD Corp. It operates as part of the technology sector. The firm serves consumers around the world.

The company operates through the software and hardware segments. It is focused on the development of critical communication solutions and provides a platform which offers geo-targeted, multi-modal cellphone alerts with vocal clarity. Its principal markets are Asia, the Middle East, Europe, North and South America.

The enterprise’s offerings include a product line that’s software-based dubbed Genasys Emergency Management; and an emergency response solution known as Integrated Mass Notification Systems, which unite Genasys’ speaker system hardware with GEM software. It also provides a software application dubbed the National Emergency Warning Systems, which sends emergency alerts to the public via different mobile carriers; and GEM software to social media, emails, television, voice calls, desktop alerts, text messages and panic buttons. The enterprise also offers long range acoustic devices, including acoustic hailing devices which are used to project audible voice messages and sirens. It sells its products to commercial firms, end-users, militaries and governments.

The company recently released its latest financial results, which show increases in its year-over-year revenue for 2022. It is currently focused on growing its SaaS (Software-as-a-service) business which will encourage more investments into the company.

Genasys Inc. (GNSS), closed Monday's trading session at $3.13, off by 6.006%, on 40,357 volume. The average volume for the last 3 months is 40,357 and the stock's 52-week low/high is $2.4001/$7.30.

Passage Bio (PASG)

StreetInsider, MarketBeat, Zacks and FreeRealTime reported earlier on Passage Bio (PASG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Passage Bio Inc. (NASDAQ: PASG) is a genetics medicine firm that is focused on the development of transformative therapies for illnesses affecting the central nervous system.

The firm has its headquarters in Philadelphia, Pennsylvania and was incorporated in July 2017 by James M. Wilson, Aditya Kohli, David A. Socks, Tadataka Yamada and Stephen P. Squinto. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States, with a focus on consumers in the state of Pennsylvania.

The company is party to a collaboration agreement as well as a clinical supply and development services agreement with Catalent Maryland Inc. It is also party to a strategic collaboration with the Trustees of the Gene Therapy Program at the University of Pennsylvania.

The enterprise’s product pipeline includes PBCM06, which has been developed to treat Charcot-Marie-Tooth Type 2A; PBAL05 for treating amyotrophic lateral sclerosis; and PBML04 for treating metachromatic leukodystrophy. It also develops PBFT02, which uses AAV1 capsids to transport a gene encoding progranulin to the brain, to treat FTD-GRN (fronto-temporal dementia caused by a deficiency of progranulin). This is in addition to developing PBGM01, which uses AAVhu68 capsids to ferry beta-galactosidase; a gene encoding lysosomal acid, to the brain and peripheral tissues. Furthermore, it develops PBKR03 for the treatment of Krabbe disease.

The firm is currently focused on advancing its research and development programs, in partnership with the Gene Therapy Program. This move will open the firm up to new opportunities, which will bolster its growth significantly and benefit its shareholders.

Passage Bio (PASG), closed Monday's trading session at $2.49, off by 0.796813%, on 255,873 volume. The average volume for the last 3 months is 250,917 and the stock's 52-week low/high is $2.46/$19.84.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, StocksEarning, Kiplinger Today, QualityStocks, StockMarketWatch, TradersPro, BUYINS.NET, The Street, MarketBeat, Trades Of The Day, TopPennyStockMovers, Daily Trade Alert, SmallCapVoice, Small Cap Firm, VectorVest, Eagle Financial Publications, Cabot Wealth and PoliticsAndMyPortfolio reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent survey has found that about one-third of adults in America would consider purchasing an electric vehicle if they were in the market for a car. However, roughly 40% admitted that they wouldn’t consider the purchase of an electric car. The survey was carried out by CBSNews/YouGov, with a sample of 2,062 adult residents in the United States. The interviews were conducted between April 5–8, 2022.

Those surveyed cited the increasing price of gas as a major reason for wanting electric cars, coupled with the belief that electric cars were better for the environment. Overall, however, higher gas prices have not caused more individuals to consider the purchase of an electric vehicle over a gas-powered vehicle.

The survey found that even among individuals who cited gas prices as a reason they felt the economy was in a bad state, a large number would prefer buying a gas-powered vehicle over an electric or hybrid vehicle.

Past polls have highlighted a number of practical reasons as to why people wouldn’t consider an electric vehicle, with the cost of these vehicles being a major reason why individuals wouldn’t consider their purchase. Additionally, views on energy policies also inform whether or not individuals would consider buying an electric car. The survey found that those who felt that policies should encourage the use of electricity from wind and solar sources rather than oil or coal were more likely to consider buying a hybrid or an electric car.

On the other hand, the survey also found that those who felt that energy policies in the United States shouldn’t encourage the use of green-energy sources and would instead prefer that they encourage power from coal or oil, were less likely to consider purchasing a hybrid or electric car.

For a long time now, people who profess being affiliated to a specific party have held different opinions on how America should deal with environmental issues and climate change. The survey found that in comparison to Republicans, Democrats were more likely to view climate change as an urgent issue that needed to be dealt with, which is why they were more likely to consider the purchase of an electric vehicle.

The nationally representative sample included in the survey was weighted according to education, race, age and gender, based on the 2020 presidential vote, the Current Population Survey and the U.S. Census American Community Survey.

As the cost of acquiring an EV gradually drops, we are likely to see more electric vehicles being produced by sector players such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) as EV adoption becomes widespread in all segments of the automotive market.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Monday's trading session at $1.87, up 2.7473%, on 1,156,215 volume. The average volume for the last 3 months is 1.145M and the stock's 52-week low/high is $1.64/$4.95.

Compass Minerals International Inc. (CMP)

SmarTrend Newsletters, MarketBeat, The Online Investor, Daily Trade Alert, Trades Of The Day, Marketbeat.com, Kiplinger Today, InvestorPlace, The Street, Zacks, StreetAuthority Daily, StreetInsider, MarketClub Analysis, All about trends, Schaeffer's, The Stock Dork, Top Pros' Top Picks, Insider Wealth Alert, Wyatt Investment Research, Daily Market Beat, CRWEFinance, BUYINS.NET, Barchart and Daily Wealth reported earlier on Compass Minerals International Inc. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Magnesium sulphate, also known as Epsom salt, has a number of applications across the food processing, agricultural and pharmaceutical sectors. Projections from a recently published market study by Future Market Insights (FMI) shows that the magnesium sulphate market will grow significantly in the short term, with compound annual growth rates of 5.8% and 5.3% in value terms and volume terms, respectively.

As the population around the world grows, the scope of pharmaceutical and food industries is expanding significantly. Magnesium sulphate is currently used to manufacture fertilizers and nutraceuticals. This is in addition to being used to prevent and treat seizures and low blood magnesium in women suffering from eclampsia.

The market is expected to enjoy a positive growth curve, with most of the demand being generated from emerging economies in countries such as China, Brazil and India. This is mainly due to the concentration of their populations and the subsequent development of the healthcare and agricultural industries.

It is expected that solid magnesium chloride crystals will dominate the market, controlling almost 80% of the product’s international market share. The use of agriculture-grade magnesium sulphate in manufacturing fertilizers is also expected to increase. Additionally, the demand for heptahydrate magnesium sulphate is expected to increase, due to its use in various applications.

One FMI analyst noted that vendors were committed to improving long-term contracts and partnerships with providers of raw materials in order to help produce goods at cheap prices, which would help both parties do business in the competitive environment. However, the current coronavirus pandemic has brought uncertainty in the market and decreased the likelihood that service and industrial sectors will be able to resume their operations on full-time basis. This may create issues in the magnesium sulphate market.

Industrial output for industries such as food processing, construction, paper and pulp, and cement has been heavily impacted by the pandemic on the production and supply front, which is expected to reduce demand for magnesium sulphate for some product applications. Additionally, halting of magnesium mining operations has also brought on shortages, especially in the Chinese and American markets. It is expected that in the long term, however, that the market will recover.

Players in the market are currently focused on establishing sales offices in emerging economies and heavily relying on distributors to help them promote and market their products. Prominent players such as K+S Aktiengesellschaft and PQ Corp remain concentrated on mature markets in Europe and the United States as they deepen their penetration in those markets while also ramping up production.

The projected growth in the dominance of magnesium chloride over the coming years favors entities such as Compass Minerals International Inc. (NYSE: CMP), which have specialized in the extraction of this increasingly vital mineral.

Compass Minerals International Inc. (CMP), closed Monday's trading session at $60.91, off by 3.6082%, on 303,110 volume. The average volume for the last 3 months is 265,137 and the stock's 52-week low/high is $47.10/$75.44.

The QualityStocks Company Corner

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Senate Majority Leader Chuck Schumer has made it clear that he is a strong supporter of comprehensive marijuana reform at the federal level. For the past couple of months, he has been working with Senator Cory Booker and Senate Finance Committee Chair Ron Wyden on a bill that would federally legalize cannabis and regulate sales. Dubbed the Cannabis Administration & Opportunity Act (CAOA), Schumer’s bill was first unveiled in 2021 to mixed reviews. The draft bill intended to deschedule cannabis at the federal level, expunge prior nonviolent cannabis convictions from people’s records, allow states to continue running their own cannabis markets, and even allow people with prior cannabis convictions to petition for resentencing. It would also use some of the funds raised from marijuana sales for programs that support communities that were disproportionately affected by the war on drugs. If this delay results in better chances of the measure being passed, the wait will be worthwhile to the entire cannabis industry, including major sector players such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF).

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Monday's trading session at $0.2291, up 3.6652%, on 128,692 volume. The average volume for the last 3 months is 128,692 and the stock's 52-week low/high is $0.2088/$1.27.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and Zyn
  • So far, the company’s animal studies have evidenced that the technology delivers outstanding results, including faster delivery, an increase in the quantity of peak nicotine delivered, higher brain levels of nicotine, and enhanced bioavailability
  • In its most recent study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls
  • Lexaria’s research aims to support a safe alternative to the harmful, antiquated pulmonary nicotine administration practices, which claim 7.7 million lives annually 

Since commencing in vivo studies evaluating its DehydraTECH technology for oral nicotine applications in 2018, global innovator Lexaria Bioscience (NASDAQ: LEXX) has primarily focused on animal studies that have proven the technology’s effectiveness in promoting faster absorption, higher peak absorption, and greater overall quantities of nicotine, on average, in the blood than concentration-matched control formulations. Building on the successes of these animal studies, Lexaria has now set its sights on a human nicotine study, NIC-H22-1, which is expected to begin dosing this summer (https://cnw.fm/4KP6s). 

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $3.05, up 1.6667%, on 132,029 volume. The average volume for the last 3 months is 132,029 and the stock's 52-week low/high is $2.64/$12.50.

Recent News

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF)

The QualityStocks Daily Newsletter would like to spotlight DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF).

DIGIMAX GLOBAL INC. (the "Company" or "DigiMax") (DBKSF) is pleased to announce that it has signed a non-binding memorandum of understanding ("MOU") dated April 25, 2022, to acquire all of the issued and outstanding shares of Israel-based Spetz Tech Ltd. ("Spetz"), a technology company which has developed artificial intelligence ("AI") software to operate a revolutionary and fast-growing mobile application that connects members of the public to available, top-rated tradespeople, service providers and professionals in their area immediately or at any scheduled time. In consideration for all of the issued and outstanding shares of Spetz, DigiMax will issue 250 million common shares of the Company, which will amount to approximately 47% of the outstanding shares of the Company after the acquisition is complete (the "Transaction"). The number of shares is not contingent on the trading price of DigiMax shares.

DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals.

The company offers financial, business, and human capital AI predictive solutions to businesses, institutions, and consumers to improve decision-making.

The DigiMax core solutions are:

  1. CryptoHawk AI – CryptoHawk is a deep learning AI solution (SaaS) that monitors and analyzes live select cryptocurrencies and financial markets. The CryptoHawk AI solution is offered to retail clients as a monthly subscription. Generated data provides subscribers with price trend predictions for better investment strategies.
  2. Cryptocurrency Hedge Fund – A long/short cryptocurrency hedge fund for high net worth, institutional, and family office clients was launched on September 1, 2021. The company’s crypto hedge fund earns clients’ management and overall performance fees.
  3. Projected Personality Interpreter (PPI) – DigiMax solutions utilize AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services by measuring and correlating personal attributes.
  4. Navee Predict – DigiMax data scientists provide companies with the unprecedented power of enhancing decision-making by analyzing, detecting changes and forecasting patterns.

The company’s team has extensive experience in finance, trading, machine learning (ML), neural language processing, AI, big data, and cryptocurrency technology. DigiMax leverages AI and its expert team to translate data into actionable predictive insights across the financial, business, and human dimensions, enhancing the decision-making capacity of organizations. DigiMax is an official IBM Watson partner with more than 30 years in data science and artificial intelligence.

Solutions

Business and Financial Capital Solutions

CryptoHawk AI

CryptoHawk.ai is a cryptocurrency price and trend prediction solution offered as a web application (https://cryptohawk.ai) and a mobile application by the end of 2021. The value for the user is to capture gains and take advantage of volatility while reducing risk and engaging in smarter and simpler trading.

The key features:

  • Trend Prediction Indicator (“TPI”)
    The TPI is a superior model that leverages the cryptocurrencies analyzed by the AI and other market-driven data and policies to produce actionable predictions in the form of:
    • Prediction cards
    • Cryptocurrency graphs with optional market indicators
    • Email/SMS alerts
  • Trend Watch
    Trend Watch is a one-week look ahead machine learning prediction for a select portfolio of mature cryptocurrencies. Trend Watch predicts a trend being UP or DOWN and provides a price target. Users have access to:
    • A list of select cryptocurrencies with predictive graphs

The system alerts investors through email and text messages when a price trend changes, allowing users to act confidently.

Cryptocurrency Hedge Fund

On September 1, 2021, DigiMax launched its Cryptocurrency Hedge Fund to offer high net worth, institutional, and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms. The official launch is expected in the coming months.

The fund is led by 40-year hedge fund veteran Ian Hamilton and has an experienced investment and fund management team. This actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies.

AI Business Prediction as a Service

The company offers predictive insights to businesses through automation and its innovative and proprietary AI and ML technology. Traditional models are expensive, because they are created and developed by data scientists dedicated to solving specific business questions that require costly customization and weeks, if not months, of development. With DigiMax, companies have access to solutions and services at a fraction of the price of traditional and experimental approaches. By combining AI with ML prediction technology, the company delivers insights on:

  • Sales forecasts
  • Optimal inventory levels
  • Supply chain management
  • Invoice payment projections
  • Targeted segmentation for marketing campaigns

Human Capital Solutions

AI-Powered Projected Personality Interpreter

The Projected Personality Interpreter (“PPI”) evaluates and improves customers’ workforce, brand and culture by revealing the personality traits and sentiment buried in human expression. The PPI empowers organizations with comparative insight for better hiring decisions, reducing employment attrition and improving workplace culture.

PPI provides a comprehensive and complete solution, offering:

  • Recruitment campaign management
  • Custom questionnaires, desirable traits recipes, and group likenesses
  • Detailed personality reports to compare and contrast peers
  • API for advanced integration with alternative systems of record

DigiMax leverages IBM Watson and a custom algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, providing hiring managers with a comprehensive report that improves decision making and takes the bias out of the process. The company’s solution is currently in use by 17 law enforcement agencies in North America and is used across the 10 global recruitment brands of Shepherd Search Group.

Market Overview

The AI industry has a five-year CAGR of 18.4%, with revenues projected to reach $37.9 billion by 2024. Some more optimistic forecasts have the market worth as much as $15 trillion by 2030. It’s estimated that 80% of all emerging technologies in 2021 have AI foundations. About 40% of all businesses use AI in their operations. According to Industry Ark, artificial intelligence use in the recruitment market was valued at $580 million in 2019.

Management Team

Chris Carl, CEO

Chris Carl has over 20 years of experience as a public-company CEO and has built several successful businesses across multiple categories. He has a proven ability to lead and has a track record of execution, revenue growth, and value creation.

Thierry Hubert, CTO

Thierry Hubert has 30 years of technology experience with Fortune 100 companies worldwide and is an early pioneer in applying artificial intelligence to solve big data and unstructured information challenges with IBM as a Director of R&D in emerging technology, knowledge management, and process innovation. He has received awards, recognitions, and grants that contributed to his ongoing collaboration with industry leaders.

David Bhumgara, CFO

David Bhumgara is a senior finance executive with over 25 years of leadership experience and proven expertise in finance, financial reporting, accounting, corporate finance, budgeting, financial modeling, and mergers & acquisitions.

Damon Stone, Trading Strategy Advisor

Damon Stone is an experienced stock and crypto trader who works very closely with the Cryptodivine.ai data science team as a subject matter expert. During 15 years at Merrill Lynch as a market maker and proprietary trader, he traded many different sectors, culminating in heading up a $250 million trading desk.

Ross Power, Senior Innovation Engineer
Ross Power is an experienced technical system architect with a demonstrated history of working on advanced technologies, including AI algorithms, IoT solutions, 3D printing, Innovation in BCI (Brain-Computer Interfacing), and RC flight and navigation systems.

DigiMax Global Inc. (DBKSF), closed Monday's trading session at $0.035, even for the day, on  volume. The average volume for the last 3 months is 13,101 and the stock's 52-week low/high is $0.021/$0.215.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

  • Each autonomous security robot subscription comes with the Knightscope Security Operations Center (“KSOC”), which provides service opportunities, including recording/streaming, people detection, facial recognition, thermal anomaly detection, license plate recognition, and more
  • Interested users can see the technology first-hand by visiting the website or by finding one of Knightscopes’ Robot Roadshow stops near them or requesting a stop in their town
  • The Robot Roadshow is a virtually-led experience with real interactions for prospective clients with the ASR models and KSOC interface

The market for security robots was valued at $8.87 billion in 2020 and is expected to continue growing at a CAGR of approximately 14%, to reach $19.77 billion by 2026 (https://ibn.fm/8bvum). North America is anticipated to take up most of the market during the forecast period, and Knightscope (NASDAQ: KSCP) is uniquely positioned to capitalize on this growing sector. Knightscope is a leader in developing autonomous security capabilities, uniquely combining self-driving technology, robotics, artificial intelligence, and electric vehicles.

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Monday's trading session at $4.08, off by 2.1583%, on 233,506 volume. The average volume for the last 3 months is 233,506 and the stock's 52-week low/high is $3.91/$27.50.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that the company was featured in a recently published article by The Buzz EV News that highlights Mullen’s progress and its plans for the upcoming FIVE EV Crossover. The piece features excerpts from a Q&A roundtable interview with David Sickels, digital managing editor from The Buzz EV News, where David Michery, Mullen’s CEO and chairman, Jason Putnam, VP of marketing, and Marian Petrelecan, VP of vehicle engineering, sat down to discuss different aspects of Mullen Automotive and its FIVE EV. “We had a great discussion with David from The Buzz,” Michery said. “I appreciate The Buzz taking time to get to know more about Mullen Automotive and offering their readers a chance to also learn more about our company and our EV vision.” To view the full press release, visit https://ibn.fm/nmE7b

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $1.39, off by 6.0811%, on 63,987,351 volume. The average volume for the last 3 months is 61.468M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

BlockQuarry Corp. (OTC: BLQC)

The QualityStocks Daily Newsletter would like to spotlight BlockQuarry Corp. (OTC: BLQC).

BlockQuarry (OTC: BLQC), a Texas-based company with primary commercial-stage operations in cryptocurrency mine hosting and self-mining in the Southeast United States, today announced financial and operational performance highlights for the twelve months ended Dec. 31, 2021. The company also announced the full launch of its Phase One 20MW hosting infrastructure at its Southeast U.S. cryptocurrency mining site, which will drive approximately $9.5 million in annual revenues going forward. “2021 was a breakthrough year for the company, and the investments we made during that period are already starting to pay big dividends as we begin to collect on the implementation of our Phase One hosting infrastructure,” said Alonzo Pierce, president and chair of BlockQuarry. “The topline exploded higher last year, and the bottom line is set to swing in our favor sharply as we get past our major fixed costs.” To view the full press release, visit https://ibn.fm/ht5xP

BlockQuarry Corp. (OTC: BLQC), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

  • February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
  • February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
  • February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
  • March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

  • Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
  • Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
  • PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
  • Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

BlockQuarry Corp. (BLQC), closed Monday's trading session at $0.8425, off by 3.1052%, on 79,048 volume. The average volume for the last 3 months is 79,048 and the stock's 52-week low/high is $0.19/$3.78.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Currently, there are a number of ongoing and planned clinical trials looking into the use of psychedelic therapies in the treatment of post-traumatic stress disorder (PTSD). Most of these trials focus on one particular psychedelic, MDMA, which is commonly known as ecstasy. However, other psychedelic compounds have also shown therapeutic potential, especially with regard to treating trauma. Given that trauma comes in different forms, researchers are focused on addressing the primary/root causes of trauma using psychedelics. Here we discuss broad categorizations of trauma being targeted by psychedelics. A number of companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), are making progress in their efforts to identify psychedelic remedies for various mental illnesses, and it may not be long before approved therapies of this nature hit the market.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $0.71, off by 1.6484%, on 440,323 volume. The average volume for the last 3 months is 437,473 and the stock's 52-week low/high is $0.70/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Researchers have highlighted the important role that some plants play in the manufacture of cancer drugs and why these new sources and plant resources need to be maintained in an effort to avoid overexploitation. For instance, Kew Gardens researcher Melanie-Jayne Howes stated that a chemical found in the Pacific yew tree was used to develop an anti-cancer drug called paclitaxel, which is effective in the treatment of breast and ovarian cancers. However, the chemical is produced in low volumes, which led to many trees being cut down in order to manufacture these drugs. Now, the Pacific yew tree is classified as near threatened. At the moment, all possible sources of cancer remedies are being sought by plenty of bio-tech companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) in order to offer the help that millions around the world need in their fights against the cancers afflicting them.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.3299, off by 1.5224%, on 247,383 volume. The average volume for the last 3 months is 247,383 and the stock's 52-week low/high is $0.2453/$2.68.

Recent News

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF) is a company focused on developing institution-grade payment infrastructure, liquidity and solutions for the Lightning Network, a layer 2 payment protocol on top of the blockchain that facilitates almost instant microtransactions with lower associated fees. The Lightning Network dramatically increases the blockchain transaction time for Bitcoin from approximately seven transactions per second to 1,000,000 per second. In comparison, a major credit card company has a network capacity of 65,000 transactions per second in terms of fiat currency. “LQwD is leveraging the Lightning Network and providing a proprietary platform-as-a-service (‘PaaS’) that speeds up transaction times, is secure and facilitates payments anywhere in the world. LQwD’s PaaS was created to be user-friendly – with little to no technological prerequisite required,” a recent article reads. To view the full article, visit https://ccw.fm/nAorP

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Monday's trading session at $0.1511, off by 1.4993%, on 8,569 volume. The average volume for the last 3 months is 8,569 and the stock's 52-week low/high is $0.133/$4.00.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety
  • The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media
  • The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal
  • Delic recently received Health Canada authorization to obtain 60 grams of psilocybin mushrooms for its purposes and to conduct research using other psychedelics, such as MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B.

On April 19, 1943, a Swiss chemical researcher experienced what has come to be known as “the world’s first intentional acid trip” as he experimented with the hallucinogenic effects of lysergic acid diethylamide (“LSD“) while riding his bicycle home from work. The day subsequently became celebrated as “Bicycle Day” by the drug’s users (https://ibn.fm/WN2av). Some 50 years after LSD and other psychedelic drugs reached their peak use in the United States, psychedelics are enjoying a new resurgence in popularity and possible legal authorization as medical researchers examine their potential to treat difficult mental disorders — particularly where psilocybin, the naturally hallucinogenic prodrug compound in “magic mushrooms,” is concerned (https://ibn.fm/mvupb). Psychedelic wellness company Delic Holdings (CSE: DELC) (OTCQB: DELCF) is a leader in new medicines and treatments for a modern world, making the health benefits more accessible and affordable to patients, and reframing the conversation around psychedelics. 

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Monday's trading session at $0.07075, off by 10.267%, on 76,743 volume. The average volume for the last 3 months is 76,743 and the stock's 52-week low/high is $0.03308/$0.398.

Recent News

SPYR Inc. (OTCQB: SPYR)

The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

  • SPYR Inc. recently announced acquisition plans for the coming months that it expects to increase its revenue streams
  • SPYR’s targets include a proprietary lighting technologies developer and a proprietary high-value asset tracking technologies developer for use in the construction, agriculture, asset management, police, defense, energy and cold-chain industries
  • The deals are in the preliminary stages, but SPYR is working to complete a non-binding letters of intent in the near future
  • SPYR subsidiary Applied Magix completed a national TV ad campaign for its first branded product, MagixDrive, which serves as a wireless adapter between an iPhone and a vehicle’s CarPlay infotainment system to increase ease of access to apps and other functionality while driving

SPYR (OTCQB: SPYR), a technology focused holding company, is preparing to add additional revenue streams to its operations, paving the way for a possible boost to shareholder value this year if its plans come to fruition. SPYR (OTCQB: SPYR), dba SPYR Technologies, and its Applied Magix Inc. subsidiary recently celebrated two additions to the company’s advisory board – Michael Teitelbaum and Siobhán Ellis. “The two additions will aid in SPYR’s continued effort to identify and target acquisitions to grow its footprint in the industry and expand its product offering to consumers, including companies developing artificial intelligence (‘AI’) and smart technology products,” a recent article reads. Teitelbaum is the senior brand integrity manager at Jazzwares, while Ellis lives in the U.K. and utilizes HomeKit products to make her home smarter, which presents challenges as her home was built in the 1850s. SPYR CEO Tim Matula commented: “Everyone here at SPYR is working as part of a cohesive team towards the same goal — building a better SPYR and bringing the best products and services to our customers.” To view the full article, visit https://ibn.fm/UHMSU.

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.

Products

The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Monday's trading session at $0.0448, off by 12.8405%, on 918,139 volume. The average volume for the last 3 months is 555,035 and the stock's 52-week low/high is $0.02355/$0.1249.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

  • Friendable acquired Artist Republik and FeaturedX in January 2022 – bringing together a full-service artist offering without the need for label control
  • Fan Pass Live artist platform lets artists earn revenue for all aspects of their music, including fan subscriptions, contests, ticket sales, tips, and more
  • For April, Fan Pass Live is offering the top five artists with the most ticket sales the opportunity to win free, unlimited music distribution for a year
  • Friendable will be integrating a non-fungible token (“NFT”) offering in the future, adding another stream of revenue for artists, by enabling fans to trade and sell these tokens
  • The global music streaming market was valued at $29.45 billion in 2021 and is expected to continue growing, with technological advances playing a major role in the expansion, especially the use of smart devices for distribution and production

Friendable (OTC: FDBL), is addressing an unmet need in the music industry for independent artists. The current structure requires artists to sign with labels, booking agents, and managers to acquire the resources necessary to record and distribute their music – not with Friendable’s 360 artist offering. Statistics show that most artists lose 90% of their streaming revenue to record labels, 10% to booking agents, and 15%-20% is spent in manager fees. Friendable’s 360 offerings are working with independent artists to help them take control of their music once more.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Monday's trading session at $0.000532, off by 11.3333%, on 17,250,457 volume. The average volume for the last 3 months is 17.25M and the stock's 52-week low/high is $0.0005/$0.0209.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.